Amendment and Mail Process Complete

RIABNI

Amgen Inc.

Amendment and Mail Process Complete

Trademark Snap Shot Amendment & Mail Processing Stylesheet
(Table presents the data on Amendment & Mail Processing Complete)

OVERVIEW

SERIAL NUMBER 88182290 FILING DATE 11/05/2018
REG NUMBER 0000000 REG DATE N/A
REGISTER PRINCIPAL MARK TYPE TRADEMARK
INTL REG # N/A INTL REG DATE N/A
TM ATTORNEY BUSH, KAREN K
L.O. ASSIGNED 108

PUB INFORMATION

RUN DATE 07/26/2019
PUB DATE N/A
STATUS 647-EXAMINERS AMENDMENT - MAILED
STATUS DATE 07/25/2019
LITERAL MARK ELEMENT RIABNI

DATE ABANDONED N/A DATE CANCELLED N/A
SECTION 2F NO SECTION 2F IN PART NO
SECTION 8 NO SECTION 8 IN PART NO
SECTION 15 NO REPUB 12C N/A
RENEWAL FILED NO RENEWAL DATE N/A
DATE AMEND REG N/A


FILING BASIS

FILED BASIS CURRENT BASIS AMENDED BASIS
1 (a) NO 1 (a) NO 1 (a) NO
1 (b) YES 1 (b) YES 1 (b) NO
44D NO 44D NO 44D NO
44E NO 44E NO 44E NO
66A NO 66A NO

NO BASIS NO NO BASIS NO


MARK DATA

STANDARD CHARACTER MARK YES
LITERAL MARK ELEMENT RIABNI
MARK DRAWING CODE 4-STANDARD CHARACTER MARK
COLOR DRAWING FLAG NO

CURRENT OWNER INFORMATION

PARTY TYPE 10-ORIGINAL APPLICANT
NAME Amgen Inc.
ADDRESS One Amgen Center Drive
Thousand Oaks, CA 913201799
ENTITY 03-CORPORATION
CITIZENSHIP Delaware

GOODS AND SERVICES

INTERNATIONAL CLASS 005
          DESCRIPTION TEXT Pharmaceutical preparations for treatment of oncologic, inflammatory and auto-immune diseases and disorders; pharmaceutical preparations for treatment of arthritis; pharmaceutical preparations for treatment of diseases and disorders of the blood, skin, bone marrow, nervous system, immune system and joints; pharmaceutical preparations for treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), pemphigus vulgaris (PV), multiple sclerosis (MS), and stem cell transplantation

GOODS AND SERVICES CLASSIFICATION

INTERNATIONAL CLASS 005 FIRST USE DATE NONE FIRST USE IN COMMERCE DATE NONE CLASS STATUS 6-ACTIVE

MISCELLANEOUS INFORMATION/STATEMENTS

CHANGE IN REGISTRATION NO

PROSECUTION HISTORY

DATE ENT CD ENT TYPE DESCRIPTION ENT NUM
07/25/2019 XAEC I EXAMINER'S AMENDMENT ENTERED 012
07/25/2019 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED 011
07/25/2019 GNEA O EXAMINERS AMENDMENT E-MAILED 010
07/25/2019 CNEA R EXAMINERS AMENDMENT -WRITTEN 009
03/07/2019 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED 008
03/07/2019 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED 007
12/13/2018 GPRN O NOTIFICATION OF PRIORITY ACTION E-MAILED 006
12/13/2018 GPRA F PRIORITY ACTION E-MAILED 005
12/13/2018 CPRA R PRIORITY ACTION WRITTEN 004
12/11/2018 DOCK D ASSIGNED TO EXAMINER 003
11/20/2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM 002
11/08/2018 NWAP I NEW APPLICATION ENTERED IN TRAM 001

CURRENT CORRESPONDENCE INFORMATION

ATTORNEY Timothy J. Gaul
CORRESPONDENCE ADDRESS Timothy J. Gaul
Amgen Inc.
One Amgen Center Drive
Trademark Operations
Thousand Oaks, CA 91320-1799
DOMESTIC REPRESENTATIVE NONE

Amendment and Mail Process Complete [image/jpeg]


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed